Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report
<h3>Background</h3><p dir="ltr">The Moderna COVID-19 vaccine was approved in December 2020 after it was proven safe and highly effective in preventing symptomatic COVID-19 infection. Later, several cases reported the incidence of thrombosis and thrombocytopenia after the...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513515093491712 |
|---|---|
| author | Eman Elmekaty (14777932) |
| author2 | Asad Abusweireh (17191855) Rand Alattar (18507101) Tasneem Abdallah (17380486) Mehdi Errayes (18507103) Muna Al-Maslamani (12184467) Alaaeldin Abdelmajid (12535542) |
| author2_role | author author author author author author |
| author_facet | Eman Elmekaty (14777932) Asad Abusweireh (17191855) Rand Alattar (18507101) Tasneem Abdallah (17380486) Mehdi Errayes (18507103) Muna Al-Maslamani (12184467) Alaaeldin Abdelmajid (12535542) |
| author_role | author |
| dc.creator.none.fl_str_mv | Eman Elmekaty (14777932) Asad Abusweireh (17191855) Rand Alattar (18507101) Tasneem Abdallah (17380486) Mehdi Errayes (18507103) Muna Al-Maslamani (12184467) Alaaeldin Abdelmajid (12535542) |
| dc.date.none.fl_str_mv | 2024-05-26T06:09:32Z |
| dc.identifier.none.fl_str_mv | 10.57945/manara.25709391.v1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/conference_contribution/Venous_Thromboembolism_after_Moderna_COVID-19_Vaccination_A_Case_Report/25709391 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Coronavirus COVID-19 Venous Thromboembolism Vaccine Moderna Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| dc.title.none.fl_str_mv | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report |
| dc.type.none.fl_str_mv | Text Conference contribution info:eu-repo/semantics/publishedVersion text conference object |
| description | <h3>Background</h3><p dir="ltr">The Moderna COVID-19 vaccine was approved in December 2020 after it was proven safe and highly effective in preventing symptomatic COVID-19 infection. Later, several cases reported the incidence of thrombosis and thrombocytopenia after the vaccine, which raised some concerns about its safety on the long-term. We aimed to report a case of a patient who developed extensive pulmonary embolism (PE) and deep vein thrombosis (DVT) after 18 days of receiving the second dose of Moderna COVID-19 vaccine.</p><h3>Case presentation</h3><p dir="ltr">A 32-years old Bangladeshi male, not known to have chronic illness, presented to the hospital with productive cough, subjective fever, excessive sweating, and occasional hemoptysis for 18 days, which all started 1 day after receiving his second dose of Moderna COVID-19 vaccine. Upon presentation, he was critically ill, hypoxic, tachypneic, and tachycardiac. Given the history of recent vaccination, with the presenting symptoms and elevated D-dimer level of 4.59 mg/L, pulmonary embolism was suspected, so urgent computed tomography pulmonary angiogram was done and indicated acute PE (Figure1). Furthermore, lower limb ultrasound doppler showed findings suggestive of acute DVT; though, serial complete blood counts showed no evidence of thrombocytopenia neither at presentation nor after that.</p><h3>Discussion</h3><p dir="ltr">Vaccine-induced thrombosis and thrombocytopenia have been reported previously in healthy individuals after receiving adenovirus-based SARS-CoV-2 vaccines. They were mostly occurring 5 to 30 days after vaccine administration. A previous case report described thrombosis and thrombocytopenia that developed after m-RNA vaccine (Moderna); however, our case reported thrombosis without thrombocytopenia after Moderna COVID-19 vaccination. Generally, it is difficult to establish a direct association between this serious thrombotic event and exposure to the Moderna COVID-19 vaccine from few case reports among millions of vaccine doses administered globally.</p><h3>Conclusion</h3><p dir="ltr">This case described the possible link between Moderna vaccine and venous thromboembolism; yet further evidence is needed to confirm this association.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_4f316c85775e207bee38e1fc91b81f61 |
| identifier_str_mv | 10.57945/manara.25709391.v1 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25709391 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case ReportEman Elmekaty (14777932)Asad Abusweireh (17191855)Rand Alattar (18507101)Tasneem Abdallah (17380486)Mehdi Errayes (18507103)Muna Al-Maslamani (12184467)Alaaeldin Abdelmajid (12535542)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesPharmacology and pharmaceutical sciencesCoronavirusCOVID-19Venous ThromboembolismVaccineModernaQatar Health Congress 2023 and the 3rd Qatar Public Health Conference<h3>Background</h3><p dir="ltr">The Moderna COVID-19 vaccine was approved in December 2020 after it was proven safe and highly effective in preventing symptomatic COVID-19 infection. Later, several cases reported the incidence of thrombosis and thrombocytopenia after the vaccine, which raised some concerns about its safety on the long-term. We aimed to report a case of a patient who developed extensive pulmonary embolism (PE) and deep vein thrombosis (DVT) after 18 days of receiving the second dose of Moderna COVID-19 vaccine.</p><h3>Case presentation</h3><p dir="ltr">A 32-years old Bangladeshi male, not known to have chronic illness, presented to the hospital with productive cough, subjective fever, excessive sweating, and occasional hemoptysis for 18 days, which all started 1 day after receiving his second dose of Moderna COVID-19 vaccine. Upon presentation, he was critically ill, hypoxic, tachypneic, and tachycardiac. Given the history of recent vaccination, with the presenting symptoms and elevated D-dimer level of 4.59 mg/L, pulmonary embolism was suspected, so urgent computed tomography pulmonary angiogram was done and indicated acute PE (Figure1). Furthermore, lower limb ultrasound doppler showed findings suggestive of acute DVT; though, serial complete blood counts showed no evidence of thrombocytopenia neither at presentation nor after that.</p><h3>Discussion</h3><p dir="ltr">Vaccine-induced thrombosis and thrombocytopenia have been reported previously in healthy individuals after receiving adenovirus-based SARS-CoV-2 vaccines. They were mostly occurring 5 to 30 days after vaccine administration. A previous case report described thrombosis and thrombocytopenia that developed after m-RNA vaccine (Moderna); however, our case reported thrombosis without thrombocytopenia after Moderna COVID-19 vaccination. Generally, it is difficult to establish a direct association between this serious thrombotic event and exposure to the Moderna COVID-19 vaccine from few case reports among millions of vaccine doses administered globally.</p><h3>Conclusion</h3><p dir="ltr">This case described the possible link between Moderna vaccine and venous thromboembolism; yet further evidence is needed to confirm this association.</p>2024-05-26T06:09:32ZTextConference contributioninfo:eu-repo/semantics/publishedVersiontextconference object10.57945/manara.25709391.v1https://figshare.com/articles/conference_contribution/Venous_Thromboembolism_after_Moderna_COVID-19_Vaccination_A_Case_Report/25709391CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257093912024-05-26T06:09:32Z |
| spellingShingle | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report Eman Elmekaty (14777932) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Coronavirus COVID-19 Venous Thromboembolism Vaccine Moderna Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| status_str | publishedVersion |
| title | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report |
| title_full | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report |
| title_fullStr | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report |
| title_full_unstemmed | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report |
| title_short | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report |
| title_sort | Venous Thromboembolism after Moderna COVID-19 Vaccination: A Case Report |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Coronavirus COVID-19 Venous Thromboembolism Vaccine Moderna Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |